FDA sets Oc­to­ber ad­comm to dis­cuss full ap­proval for Am­gen’s Lumakras to treat sec­ond-line lung can­cer

The FDA will con­vene its on­col­o­gy ad­vi­so­ry com­mit­tee in Oc­to­ber to dis­cuss Lumakras, Am­gen’s KRAS-in­hibit­ing oral med­ica­tion as a sec­ond-line treat­ment for KRAS G12C-mu­tat­ed non …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER